The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
ApexOnco Front Page
Recent articles
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
